TB-500

TB-500 is a synthetic fragment of thymosin beta-4 (TβSeq), a naturally occurring 43-amino-acid protein that is one of the most abundant proteins in human cells. The fragment used in research corresponds to the active region of the full thymosin beta-4 molecule responsible for cell migration and actin regulation. Because the full-length protein is large and difficult to manufacture, researchers and peptide labs use the short fragment as a practical stand-in. It is sold strictly for laboratory research and has not been approved by the FDA for human use.

If BPC-157 is the local repair foreman, TB-500 is the roaming repair crew that travels across the whole body. Researchers study it because thymosin beta-4 is involved in helping cells move to where they are needed — to a wound, an injury, a damaged blood vessel. People in the recovery and longevity space talk about TB-500 as the systemic counterpart to BPC-157: less site-specific, more whole-body. It became famous outside research circles through equine sports, where it has been studied (and controversially used) for racehorse recovery. Today it is one of the most-Googled research peptides in the fitness and biohacking world.

Thymosin beta-4 binds G-actin, a protein critical to cell movement and structural reorganization. By regulating actin polymerization, TB-500 supports cellular migration — letting endothelial cells, stem cells, and immune cells move into injured areas more efficiently in animal research. It is also associated with angiogenesis, downregulation of inflammatory cytokines, and increased flexibility of damaged tissue in research models. Because actin is involved in nearly every tissue, the effects in animal studies tend to be systemic rather than localized — which is exactly why researchers and online communities pair it conceptually with the more local-acting BPC-157.

Promotes cell migration, angiogenesis (new blood vessel formation), and rapid muscle/tissue repair.

1. TB-500
2. Local growth-factor and angiogenic signalling
3. Cell migration, matrix remodelling and inflammatory modulation
4. Connective-tissue, gut-lining and wound-repair endpoints

A plain-English read on how much published evidence currently exists for TB-500. These ratings describe the volume and maturity of the literature — not effectiveness, safety, or suitability for any use.

Current limitations: most compounds in this category are studied in preclinical or small-sample settings. Absence of large controlled human trials is the single biggest limitation to keep in mind when reading any summary of TB-500.

Lyophilized compounds are supplied as a dry powder. Concentration is simply the total amount in the vial divided by the volume of bacteriostatic water added:

Concentration (mg/mL) = total mg in vial ÷ mL of diluent added

Commonly supplied vial sizes

5mg or 10mg vial

Worked concentration example

5mg + 2mL BAC water → 2.5mg/mL On U-100 insulin syringe:

• • 40 units = 1.0mg
• • 80 units = 2.0mg

Run your own numbers with the reconstitution calculator — it converts vial size and diluent volume into mg/mL and mcg/mL.

The figures below are reported here descriptively, because they are the values most frequently cited in publicly available research literature and reference material. They are not instructions, not a protocol, and not a recommendation. These compounds are supplied for laboratory research use only and are not approved by the FDA for human consumption.

Commonly cited amounts

Loading: 2–5mg, 2× weekly for 4 weeks. Maintenance: 2–2.5mg weekly.

Commonly cited frequency

2× weekly during loading; weekly during maintenance

Commonly cited study duration

4 weeks loading + 4–8 weeks maintenance

Peptides are supplied freeze-dried because peptide bonds degrade far faster in solution than in a dry state. Understanding storage is part of understanding why the powder form exists at all.

• •Lyophilized powder: stored refrigerated, typically stable for months to years.
• •Reconstituted solution: refrigerated at 2–8°C, generally discussed as stable for roughly 30–60 days.
• •Heat and direct light accelerate degradation — vials are kept cool and dark.
• •Reconstituted material is not re-frozen; ice crystal formation disrupts peptide structure.
• •Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what allows multi-day storage after reconstitution.

More detail in the storage & handling guide and how peptide quality is evaluated.

• •Cardiac tissue repair after experimental ischemia
• •Wound healing and skin regeneration
• •Corneal injury and ocular surface research
• •Neurological recovery and axonal regeneration
• •Equine and animal tendon recovery (veterinary studies)
• •Anti-fibrotic and inflammatory modulation research
• •Hair follicle research models

Online, TB-500 lives next to BPC-157 in virtually every recovery thread. Forum users describe systemic 'whole body' effects compared to BPC-157's more localized profile and frequently discuss longer half-life as a practical advantage — dosing schedules in research talk are often twice per week rather than daily. It is also discussed in the context of equine racing, where it became a regulatory talking point after detection in racehorses. Biohacking communities tend to frame it as 'the recovery peptide you stack with BPC-157,' and the most common debate is whether the systemic effect is worth the longer time to reach steady state.

“The roaming repair crew.”

The dominant stack discussion is BPC-157 + TB-500 — sometimes called the 'repair pair' or 'healing stack' in forums. For connective tissue and skin discussions, GHK-Cu is often added. Advanced recovery protocols described online layer the pair on top of a GH secretagogue stack such as CJC-1295 + ipamorelin. Each combination is described in terms of complementary mechanisms (local + systemic + GH-supported repair), not as a recommendation.

TB-500 is a synthetic fragment of thymosin beta-4 studied for systemic tissue repair, actin regulation, and cell migration in animal research. It is most commonly discussed alongside BPC-157 as the systemic counterpart to that peptide's localized effects, and it remains a research-only compound not approved for human use.